Ofatumumab: a novel monoclonal anti-CD20 antibody

References

• McLaughlinPGrillo-LopezAJLinkBKRituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment programJ Clin Oncol199816282528339704735
   PubMed Web of Science ®Google Scholar
• KeatingMJO’BrienSAlbitarMEarly results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemiaJ Clin Oncol2005234079408815767648
   PubMed Web of Science ®Google Scholar
• CoiffierBLepageEBriereJCHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphomaN Engl J Med200234623524211807147
   PubMed Web of Science ®Google Scholar
• KeatingMJFlinnIJainVTherapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international studyBlood2002993554356111986207
   PubMed Web of Science ®Google Scholar
• CartronGDacheuxLSallesGTherapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc gamma RIIIa geneBlood20029975475811806974
   PubMed Web of Science ®Google Scholar
• FaragSSFlinnIWModaliRLehmanTAYoungDByrdJCFc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemiaBlood20041031472147414563637
   PubMed Web of Science ®Google Scholar
• TeelingJLFrenchRRCraggMSCharacterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomasBlood20041041793180015172969
   PubMed Web of Science ®Google Scholar
• MarcusRImrieKBelchACVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphomaBlood20051051417142315494430
   PubMed Web of Science ®Google Scholar
• van OersMHKlasaRMarcusRERituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trialBlood20061083295330116873669
   PubMed Web of Science ®Google Scholar
• CoiffierBLepageEBriereJCHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphomaN Engl J Med200234623524211807147
   PubMed Web of Science ®Google Scholar
• KayNEGeyerSMCallTGCombination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chroinc lymphocytic leukemiaBlood200710940541117008537
   PubMed Web of Science ®Google Scholar
• ByrdJCPetersonBLMorrisonVARandomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)Blood200310161412393429
   PubMed Web of Science ®Google Scholar
• RummelMJAl-BatranSEKimSZBendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphomaJ Clin Oncol2005233383338915908650
   PubMed Web of Science ®Google Scholar
• TeelingJLMackusWJWiegmanLJThe biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20J Immunol200617736237116785532
   PubMed Web of Science ®Google Scholar
• HagenbeekAGadebergOJohnsonPFirst clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: Results of a phase 1/2 trialBlood20081115486549518390837
   PubMed Web of Science ®Google Scholar
• CoiffierBLepretreSPedersenLMSafety and efficacy of ofatumumab, a fully humanized monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: A phase 1–2 studyBlood20081111094110018003886
   PubMed Web of Science ®Google Scholar
• PawluczkowyczAWBeurskensFJBeumPVBinding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTXJ Immunol200918374975819535640
   PubMed Web of Science ®Google Scholar
• CraigenJLMackusWJEnglebertsPOfatumumab, a human Mab targeting a membrane-proximal small-loop epitope on CD20, induces potent NK cell-medited ADCC. [abstract]Blood2009114687
   Web of Science ®Google Scholar
• WierdaWGKippsTJMayerJOfatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemiaJ Clin Oncol201031 [Epub ahead of print]
   Web of Science ®Google Scholar
• OsterborgABiilmann RonnBJewellRCCorrelation between serum ofatumumab concentrations, baseline patient characteristics and clinical outcomes in patients with fludarabine-refractory chronic lymphocytic leukemia (CLL) treated with single-agent ofatumumab. [abstract]Blood20091141334
   Web of Science ®Google Scholar
• WierdaWGKippsTJDurigJOfatumumab combined with fludarabine and cyclophosphamide (O-FC) shows high activity in patients with previously untreated chronic lymphocytic leukemia (CLL): Results from a randomized, multicenter, international, two-dose, parallel group, phase II trial. [abstract]Blood20091149091
   Web of Science ®Google Scholar
• HagenbeekAFayadLDelwailVEvaluation of ofatumumab, a novel human CD20 monoclonal antibody, as single agent therapy in rituximab-refractory follicular lymphoma. [abstract]Blood2009114385386
   Web of Science ®Google Scholar
• DzietczeniaJWrobelTMazurGPorebaRJazwiecBKuliczkowskiKExpression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20(+) non-Hodgkin’s lymphomaMed Oncol200987 [Epub ahead of print]
   Web of Science ®Google Scholar